Relacorilant extends survival in resistant ovarian cancer
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Relacorilant extended survival in patients with platinum-resistant ovarian cancer in a trial of 381 participants, offering a potential new option for a group with few effective treatments
- Platinum-resistant ovarian cancer typically gives patients a median survival of about one year after diagnosis, due to limited response to standard platinum-based chemotherapy
- The Lancet published findings from the clinical trial, lending peer-reviewed credibility to the observed benefits of relacorilant in this aggressive cancer subtype
- Cushing’s syndrome is the original therapeutic target of relacorilant, which functions as a cortisol-signaling modulator, suggesting a repurposing pathway for the drug
- Platinum-based chemotherapy works by using platinum compounds to block cancer cell division, but resistance develops in some ovarian cancer cases within six months
Why it matters: Patients with platinum-resistant ovarian cancer gain a promising therapeutic option in relacorilant, which directly addresses a survival gap where current treatments fail. With median survival around one year, even modest extensions could meaningfully impact patient outcomes, especially given the lack of effective alternatives.
Ask SkimNews
